"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04700631","Extracellular Vesicles as Biomarkers for Chronic Renal Failure","VE-IRC","Recruiting","No Results Available","Chronic Renal Failure|Urinary Extracellular Vesicle","Diagnostic Test: urinary extracellular vesicle concentration|Diagnostic Test: blood sample","variation of urinary extracellular vesicle concentration between both groups","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PI2020_843_0104","January 1, 2021","December 2021","December 2021","January 8, 2021",,"July 21, 2021","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04700631"
2,"NCT05127122","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS","EXIT-ARDS","Not yet recruiting","No Results Available","ARDS, Human","Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","The incidence of serious adverse events.|Number to patients with All-Cause Mortality at 28 days|Ventilator-free days at 28days|Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-EXITARDS-0003","December 2021","August 2022","August 2022","November 19, 2021",,"December 6, 2021",,,"https://ClinicalTrials.gov/show/NCT05127122"
3,"NCT04281901","Efficacy of Platelet- and Extracellular Vesicle-rich Plasma in Chronic Postsurgical Temporal Bone Inflammations","PvRP-ear","Completed","Has Results","Otitis Media Chronic|Temporal Bone","Drug: Platelet- and extracellular vesicle-rich plasma|Drug: Standard conservative treatment","Change in Inflammation Surface Area.|Change in Chronic Otitis Media Questionnaire 12 Score|Bacterial Presence","University Medical Centre Ljubljana|University of Ljubljana|University of Ljubljana, Faculty of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","0120-146/2019/5","March 20, 2019","April 15, 2020","October 14, 2020","February 24, 2020","August 13, 2020","August 3, 2021","University Medical Centre Ljubljana, Ljubljana, Slovenia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04281901/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04281901/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04281901"
4,"NCT05130983","A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,"Not yet recruiting","No Results Available","Crohn Disease|IBD - Irritable Bowel Disease","Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate","• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|monoclonal antibodies. • To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-CROHNS-0004","March 1, 2022","January 1, 2024","March 1, 2024","November 23, 2021",,"January 20, 2022",,,"https://ClinicalTrials.gov/show/NCT05130983"
5,"NCT04761562","Use of Autologous Plasma Rich in Platelets and Extracellular Vesicles in the Surgical Treatment of Chronic Middle Ear Infections",,"Recruiting","No Results Available","Otitis Media Chronic|Tympanic Membrane Perforation","Drug: Platelet- and extracellular vesicle-rich plasma|Procedure: Control group","Change of tympanic membrane perforation size|Change in Chronic Otitis Media Questionnaire 12 score|Change in hearing threshold level","University Medical Centre Ljubljana|University of Ljubljana","All","Child, Adult, Older Adult","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PVRPTY2021","February 14, 2021","September 30, 2023","September 30, 2023","February 21, 2021",,"February 21, 2021","University Medical Centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04761562"
6,"NCT04657458","Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS",,"Available","No Results Available","Covid19|ARDS|Hypoxia|Cytokine Storm","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment",,"Direct Biologics, LLC","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"DB-EAP-001",,,,"December 8, 2020",,"July 12, 2021",,,"https://ClinicalTrials.gov/show/NCT04657458"
7,"NCT04493242","Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS","EXIT-COVID19","Completed","No Results Available","Covid19|ARDS|Pneumonia, Viral","Biological: DB-001|Other: Intravenous normal saline","7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-PHASEII-001","September 24, 2020","May 1, 2021","May 22, 2021","July 30, 2020",,"January 14, 2022","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04493242"
8,"NCT05078385","Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds",,"Not yet recruiting","No Results Available","Burns","Drug: AGLE-102","Primary Objective|Secondary Objective","Aegle Therapeutics|Congressionally Directed Medical Research Programs","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGLE-102-102","July 2022","April 2024","July 2024","October 14, 2021",,"October 14, 2021",,,"https://ClinicalTrials.gov/show/NCT05078385"
9,"NCT04652531","Autologous Serum-derived EV for Venous Trophic Lesions Not Responsive to Conventional Treatments","SER-VES-HEAL","Recruiting","No Results Available","Ulcer Venous","Other: Autologous extracellular vesicles from serum","Changes in the ulcer area from baseline to eight weeks|Pain change","University of Turin, Italy","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CS2/1095/0090491","September 18, 2020","October 8, 2021","October 31, 2022","December 3, 2020",,"December 7, 2020","AOU San Giovanni Battista, Turin, Italy",,"https://ClinicalTrials.gov/show/NCT04652531"
10,"NCT03857841","A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD",,"Terminated","Has Results","Bronchopulmonary Dysplasia","Biological: UNEX-42|Biological: Phosphate-buffered saline","Number of Subjects With Treatment-emergent Adverse Events During the Post-treatment Phase (Safety and Tolerability)","United Therapeutics","All","up to 14 Days   (Child)","Phase 1","3","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNX-BP-101","October 9, 2019","May 20, 2021","May 20, 2021","February 28, 2019","October 12, 2021","October 12, 2021","University of Colorado Hospital, Aurora, Colorado, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03857841/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03857841/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03857841"
11,"NCT05116761","ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome",,"Not yet recruiting","No Results Available","Covid19|Postviral Syndrome|Dyspnea","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-POSTCOVID-0002","December 2021","August 2022","August 2022","November 11, 2021",,"December 6, 2021",,,"https://ClinicalTrials.gov/show/NCT05116761"
12,"NCT04653610","Sequential Analysis Before and After Treatment Initiation to Unravel the Role of Naturally Occurring Extracellular Vesicles in HIV Infection","Saturne-HIV","Recruiting","No Results Available","Hiv",,"Extracellular Vesicles analysis-NTA|Extracellular Vesicles analysis-microscopy|Extracellular Vesicles analysis-western blot|Extracellular Vesicles analysis-PCR|Extracellular Vesicles analysis-proteomics|Extracellular Vesicles analysis-RNAsequencing|Extracellular Vesicles analysis-reporter assays|Quantification of HIV DNA and RNA|Immunological analysis-FACS|Immunological analysis-ELISA|Gene expression analysis/transcriptomics|Microbiome monitoring|Virological analysis-FLIPS|Virological analysis-integration site","University Hospital, Ghent","All","18 Years to 65 Years   (Adult, Older Adult)",,"66","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BC-08408","January 27, 2021","January 2023","January 2025","December 4, 2020",,"June 3, 2021","Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT04653610"
13,"NCT03106246","Circulating Extracellular Vesicles Released by Human Islets of Langerhans",,"Unknown status","No Results Available","Type1 Diabetes Mellitus|Type2 Diabetes|Islet Cell Transplantation",,"Determine the levels of circulating EVs|Determine whether these EVs contain islet-specific antigens|Mutivariate analysis will be performed with patient parameters and EV parameters","McGill University Health Centre/Research Institute of the McGill University Health Centre|CHU de Quebec-Universite Laval","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-582-MUHC","December 2016","December 2018","July 2019","April 10, 2017",,"April 10, 2017","McGill University Health Center, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03106246"
14,"NCT02931045","Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction","AFFECT EV","Completed","Has Results","Myocardial Infarction","Drug: Ticagrelor|Drug: Clopidogrel","Concentration of Platelet Extracellular Vesicles/ml|Concentration of Extracellular Vesicles Exposing Fibrinogen|Concentration of Extracellular Vesicles Exposing Phosphatidylserine|Concentration of Extracellular Vesicles From Endothelial Cells|Concentration of Extracellular Vesicles From Leukocytes","Medical University of Warsaw|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","KB/112/2016","December 30, 2017","December 30, 2018","December 30, 2019","October 12, 2016","December 23, 2020","December 23, 2020","Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam, Amsterdam, Netherlands|1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02931045/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02931045"
15,"NCT05125562","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial",,"Not yet recruiting","No Results Available","COVID-19","Drug: ExoFlo","Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-EMOTECOVID-0006","February 7, 2022","December 7, 2022","December 7, 2022","November 18, 2021",,"January 4, 2022","Direct Biologics, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05125562"
16,"NCT04852653","A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer","RECC-EV","Not yet recruiting","No Results Available","Rectal Cancer|Liquid Biopsy","Procedure: Supplementary blood samples collection during the normal follow up of the patients","Positivity of the liquid biopsy|Prediction of the response of rectal cancer to neoadjuvant treatment|Genetic profile of the primary tumor predictive of the response to nCRT","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2020/21","May 2021","November 2023","November 2023","April 21, 2021",,"April 21, 2021","CHU Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04852653"
17,"NCT02797834","Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium",,"Unknown status","No Results Available","Extracellular Vesicles","Procedure: Endometrial fluid collection","Morphological characterization of the extracellular vesicles|Size distribution profiles characterization of the extracellular vesicles|Characterization of extracellular vesicles populations by specific markers|Qualitative (names) and quantitative (expression levels) information about the different biomolecules that could be present in the samples: DNA, RNA, proteins, lipids and other small metabolites.","Igenomix","Female","18 Years to 35 Years   (Adult)",,"300","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1603-IGX-017-FV","April 2016","March 2017","March 2019","June 14, 2016",,"June 21, 2016","IVI Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02797834"
18,"NCT04727593","The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol","MINDGAP","Recruiting","No Results Available","Cancer","Behavioral: Mindfulness Based Cognitive Therapy (MBCT)|Other: Treatment as Usual","Change on Extracellular Vesicles|Change on Distress|Change on Cancer antigen 15-3 (CA 15-3)|Change on Prostate-specific antigen (PSA)|Change on Carcinoembryonic Antigen (CEA).|Change on Adrenocorticotropic Hormone (ACTH).|Transcript inflammatory response genes (Interleukins, ILs, IL-1, IL-6, IL-8, IL-10, IFNγ and TNF).|Change on Analytic biomarkers (Erythrocyte number).|Change on Analytic biomarkers (PCR number).|Change on Analytic biomarkers (telomerase activity).|Change on Analytic biomarkers (hemoglobin glycosylated).|Change on Global distress|Change on quality of life|Change on fear of cancer recurrence|Change on satisfaction perceived social support|Change on emotional suppression|Change on mindfulness abilities|Change Interview|Change on smoking dependency|Change on physical activity|Change on sleep quality|Change on posttraumatic growth","Instituto Portugues de Oncologia, Francisco Gentil, Porto|European Commission|University of Coimbra|VTT Technical Research Centre, Finland|University of Oulu|Linnaeus University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","111","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPO/PI134b","September 3, 2021","October 2, 2022","March 1, 2023","January 27, 2021",,"October 14, 2021","Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT04727593"
19,"NCT04298398","Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer","MindGAP-P","Not yet recruiting","No Results Available","Cancer","Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention)","Change on Extracellular vesicles number by ultracentrifugation with sucrose cushion|Change on anxiety, depression and stress (Depression Anxiety Stress Scales, DASS21)|Change on Cancer antigen (CA 15-3)|Change on Prostate-specific antigen (PSA)|Change on Carcinoembryonic Antigen assays (CEA)|Change on Adrenocorticotropic Hormone (ACTH)|Transcript inflammatory response genes (IL-1, IL-6, IL-8, IL-10, IFNγ and TNF)|Change on Analytic biomarkers (Erythrocytes number)|Change on Analytic biomarkers (PCR number)|Change on Analytic biomarkers (telomerase activity)|Change on Analytic biomarkers (hemoglobin glycosylated (HPLC))|Change on Global distress (Clinical Outcome Routine Evaluation - Outcome Measure, CORE-OM)|Change on quality of life (Functional Assessment of Cancer Therapy, FACT)|Change on quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale, FACIT-SP)|Change on fear of cancer recurrence (Fear of Cancer Recurrence, FCR-7)|Change on satisfaction perceived social support (ESSS)|Change on emotional regulation processes (Emotion Regulation Questionnaire, ERQ, emotion suppression subscale)|Change on impact of events (Impact of Event Scale - Revised, IES-R)|Change on Mindfulness Attention and Awareness (Mindfulness Attention and Awareness Scale, MAAS)|Change on self-compassion skills (Self-Compassion Scale - Short Form, SHORT FORM)|Change Interview (Elliot, 1999)|Change on smoking dependency (Fagestrom Test)|Change on physical activity (IPAQ,The International Physical Activity Questionnaire)","Instituto Portugues de Oncologia, Francisco Gentil, Porto|Polytechnic Institute of Porto|VTT Technical Research Centre, Finland|University of Oulu|Linnaeus University|European Commission","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPO/PI134","September 1, 2021","September 2021","September 2021","March 6, 2020",,"October 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04298398"
20,"NCT04603326","FoxBioNet: ECV (Extracellular Vesicle) 004",,"Recruiting","No Results Available","Parkinson Disease","Procedure: Lumbar Puncture","Assay Evaluation","Michael J. Fox Foundation for Parkinson's Research|Indiana University|University of Rochester|University Health Network, Toronto","All","30 Years and older   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ECV-004","May 6, 2021","October 2022","October 2022","October 26, 2020",,"September 8, 2021","Northwestern University, Chicago, Illinois, United States|The Trustees of Columbia University, New York, New York, United States|Oregon Health Sciences Univeristy, Portland, Oregon, United States|The Trustees of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04603326"
21,"NCT04971447","Extracellular Vesicles and Endothelial Function in Transgender Subjects","Evinge","Not yet recruiting","No Results Available","Transgenderism","Drug: gender affirming hormonal treatment in transgender men|Drug: gender affirming hormonal treatment in transgender women","pulse wave velocity","Central Hospital, Nancy, France","All","18 Years to 49 Years   (Adult)","Not Applicable","136","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21.03.30.69624","September 2021","September 2023","January 2024","July 21, 2021",,"July 21, 2021",,,"https://ClinicalTrials.gov/show/NCT04971447"
22,"NCT04523389","Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients","ExoColon","Recruiting","No Results Available","Colorectal Cancer","Biological: analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|Other: Gathering additional information about the patient's cancer|Diagnostic Test: Diagnostic test","Prognostic role of exosomes and their contents on the survival of colorectal cancer patients|Association between the number and size of exosomes and their content on cancer stage and progression","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)",,"172","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COTTET 2020","July 1, 2020","January 2021","July 2021","August 21, 2020",,"August 21, 2020","Chu Dijon Bourgogne, Dijon, France",,"https://ClinicalTrials.gov/show/NCT04523389"
23,"NCT03608293","Smoker Extracellular Vesicles Influence on Human Bronchial Epithelial Cells","Aerotox-1","Completed","No Results Available","Smokers|Human Bronchial Epithelial Cells|Lung Pathogenesis|Biomarkers","Diagnostic Test: Broncho Alveolar Lavages (BAL)","Quantification of target mRNA expression in human bronchial epithelial cells (BEAS-2 B) exposed to EVs isolated from LBA of patients","Lille Catholic University|Universite du Littoral Cote d'Opale","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC-P0014","January 1, 2012","July 31, 2013","December 31, 2013","July 31, 2018",,"July 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03608293"
24,"NCT03262311","Pimo Study: Extracellular Vesicle-based Liquid Biopsy to Detect Hypoxia in Tumours",,"Completed","No Results Available","Cancer","Other: Hypoxia marker","Detectable pimonidazole staining","Institute of Cancer Research, United Kingdom","All","18 Years and older   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CCR4770","November 10, 2017","September 12, 2019","September 12, 2019","August 25, 2017",,"December 23, 2019","The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03262311"
25,"NCT05061212","The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis",,"Not yet recruiting","No Results Available","ARDS, Human",,"28-day mortality|Ventilator days|ICU stay","Southeast University, China","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ARDS-mtDNA EVs","October 1, 2021","September 1, 2022","December 31, 2022","September 29, 2021",,"September 29, 2021",,,"https://ClinicalTrials.gov/show/NCT05061212"
26,"NCT04327635","Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients With AMI",,"Recruiting","No Results Available","Heart Attack","Drug: PEP in Acute Myocardial Infarction","Dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of a single dose (10 mL) of PEP at escalating concentrations of extracellular vesicles delivered at a single time point (during PCI for AMI) for the treatment of downstream sequela of AMI.|Infarction scar size|Ejection fraction|Abdominal abnormalities|Alloimmune Response","Christopher J. McLeod|Rion LLC|Mayo Clinic","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 1","23","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-011636","November 2, 2021","November 2023","November 2024","March 31, 2020",,"December 2, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04327635"
27,"NCT03203512","Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles","HI-FIVE","Active, not recruiting","No Results Available","Extracellular Vesicles; Generation and Function","Dietary Supplement: Fish oil capsules|Dietary Supplement: High-oleic safflower oil capsules","Concentrations of total circulating EVs in platelet-free plasma (PFP) detected by flow cytometry|Concentrations of total circulating EVs in platelet-free plasma (PFP) detected by nanoparticle tracking analysis (NTA)|Pro-thrombotic activities of circulating EVs in PFP|Characterisation of circulating EVs in PFP and serum detected by fluorescence flow cytometry|Characterisation of circulating EVs in PFP and serum detected by fluorescence NTA|Ex vivo agonist-stimulated platelet activation detected by plate-based platelet activation and aggregation assays|Pro-thrombotic activities of platelet-derived extracellular vesicles (PEVs) prepared from the supernatants of stimulated platelets|Fatty acid composition analysis|Blood pressure|Concentrations of total triglyceride and cholesterol in plasma","University of Reading|Biotechnology and Biological Sciences Research Council","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UREC 17/18","February 16, 2018","November 30, 2019","September 30, 2020","June 29, 2017",,"March 24, 2020","University of Reading, Reading, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03203512"
28,"NCT05176366","Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis",,"Not yet recruiting","No Results Available","Ulcerative Colitis","Drug: ExoFlo","Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-ULCERATIVE-0004","March 1, 2022","January 1, 2024","March 1, 2024","January 4, 2022",,"January 20, 2022",,,"https://ClinicalTrials.gov/show/NCT05176366"
29,"NCT03228277","Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Olmutinib","Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)","Konkuk University Medical Center|Hanmi Pharmaceutical Company Limited","All","19 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KASTT005_BAL_Olita","July 17, 2017","July 31, 2018","July 31, 2019","July 24, 2017",,"August 28, 2019","Konkuk University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03228277"
30,"NCT04221997","Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.","EV-SoPRANO","Recruiting","No Results Available","Anxiety Disorders","Drug: sertraline","Number of Participants with Clinical Global Impression-Improvement Scale ≤ 2","University of Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 17 Years   (Child)","Phase 4","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Strawn EV-SoPRANO|R01HD098757","November 1, 2019","September 2024","September 2024","January 9, 2020",,"September 27, 2021","University of Columbia, New York State Psychiatric Institute, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04221997"
31,"NCT03775447","Fox BioNet Project: ECV-003",,"Completed","No Results Available","Parkinson Disease","Procedure: Lumbar Puncture","degree of LRRK2 enrichment achieved. The measure will vary depending on the method of LRRK2 enrichment used|Power analysis to guide future research|Time from IRB submission to approval by central IRB|Time from central IRB approval to site approval|Time from site selection to contract full execution|Completion of Recruitment|Proportion of samples conforming to collection|Retention","Michael J. Fox Foundation for Parkinson's Research|University Health Network, Toronto|Indiana University|University of Rochester","All","18 Years and older   (Adult, Older Adult)",,"38","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ECV-003","April 23, 2019","December 18, 2019","December 18, 2019","December 14, 2018",,"September 8, 2021","Northwestern University, Chicago, Illinois, United States|Oregon Health and Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03775447"
32,"NCT05191849","Circulating EV Long RNA Profiles in SCLC",,"Recruiting","No Results Available","Small Cell Lung Cancer","Diagnostic Test: Blood sample collection","Establish a model to predict curative effect","Fudan University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EXRNA-SCLC-2021","October 25, 2021","April 30, 2023","October 25, 2024","January 14, 2022",,"January 14, 2022","Cancer hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05191849"
33,"NCT04742608","Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Gland Carcinoma|Thyroid Gland Nodule","Procedure: Biospecimen Collection|Other: Electronic Health Record Review","Sensitivity of molecular profile of thyroid-derived extracellular vesicles|Specificity of molecular profile of thyroid-derived extracellular vesicles|Negative predictive value of molecular profile of thyroid-derived extracellular vesicles|Positive predictive value of molecular profile of thyroid-derived extracellular vesicles|Quantity of thyroid-derived extracellular vesicles captured in patients with localized, regional, and distant disease versus benign thyroid adenomas|Quantity of thyroid-derived extracellular vesicles captured in patients with excellent, indeterminate, biochemically incomplete, and structural incomplete responses to initial therapy|Combination of ribonucleic acid/deoxyribonucleic acid-based tests that can be perf thyroid-derived extracellular vesicles","Jonsson Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-002301|NCI-2021-00108","February 21, 2020","February 1, 2023","February 1, 2024","February 8, 2021",,"February 8, 2021","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04742608"
34,"NCT04164134","New Strategies to Detect Cancers in Carriers of Mutations in RB1","NIRBTEST","Recruiting","No Results Available","Retinoblastoma|Secondary Primary Malignancies After Retinoblastoma","Other: blood draw","RNA expression on platelets and allelic DNA balance of EVs in the blood of adult RB1 mutation carriers (Rb-survivors) and retinoblastoma patients (children).|RNA expression on platelets, allelic DNA balance of EVs in blood and genomic analysis on tumor tissue of RB1-mutation carriers diagnosed with a second primary malignancy.","VU University Medical Center|University Hospital, Essen|Institut Curie|Ligue contre le cancer, France","All","up to 99 Years   (Child, Adult, Older Adult)",,"396","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","129|NL8013","December 13, 2018","May 31, 2022","May 31, 2022","November 15, 2019",,"April 2, 2021","Institute Curie, Paris, France|University Hospital Essen (UHE), Essen, Germany|Amsterdam UMC, location VUmc, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04164134"
35,"NCT04026425","Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS",,"Recruiting","No Results Available","Myalgic Encephalomyelitis|Chronic Fatigue Syndrome","Other: Two-day cardiopulmonary exercise test","Volume of oxygen consumed at peak effort|Volume of oxygen consumed at ventilatory/anaerobic threshold (VAT)|Rate of work performed at peak effort|Rate of work performed at VAT|Heart rate at peak effort|Heart rate at VAT|Systolic blood pressure at seated rest|Systolic blood pressure at peak effort|Respiratory Exchange Ratio (RER) at peak effort","Ithaca College|Cornell University|Weill Medical College of Cornell University|Workwell Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","U54NS105541|5U54NS105541","August 1, 2018","June 1, 2022","August 31, 2022","July 19, 2019",,"January 10, 2022","ID Med, Torrance, California, United States|Ithaca College, Ithaca, New York, United States|Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04026425"
36,"NCT04173650","MSC EVs in Dystrophic Epidermolysis Bullosa",,"Not yet recruiting","No Results Available","Dystrophic Epidermolysis Bullosa","Drug: AGLE 102","Dose Limiting Toxicity|Wound size evaluation","Aegle Therapeutics","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EB IND","April 2022","January 2023","July 2023","November 22, 2019",,"June 24, 2021",,,"https://ClinicalTrials.gov/show/NCT04173650"
37,"NCT04223622","Effects of ASC Secretome on Human Osteochondral Explants","ASC-OA","Recruiting","No Results Available","Osteoarthritis","Biological: ASC secretome","Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers","Istituto Ortopedico Galeazzi","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ASC-OA","April 12, 2021","December 2022","December 2022","January 10, 2020",,"December 3, 2021","IRCCS Istituto Ortopedico Galeazzi, Milano, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04223622"
38,"NCT03546751","Extracellular microRNA: Biomarkers of Endothelial Dysfunction in Obese Adolescents & Adults With Obstructive Sleep Apnea",,"Not yet recruiting","No Results Available","Obstructive Sleep Apnea","Device: Continuous Positive Airway Pressure|Other: Diet And Exercise","Peripheral Arterial Tonometry - Reactive Hyperemic Index|miRNA 92a and miRNA 210 levels|miR 92a and miR 210 levels","University of California, San Diego","All","18 Years to 21 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","170408","April 1, 2019","July 30, 2024","December 31, 2024","June 6, 2018",,"June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT03546751"
39,"NCT03957252","Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer","APCaRI-05","Recruiting","No Results Available","Prostate Cancer","Diagnostic Test: Blood test: ClarityDX Prostate","Diagnostic Clinical Performance: prediction of clinically significant prostate cancer at biopsy","Nanostics|Alberta Prostate Cancer Research Initiative, APCaRI|DynaLIFE Medical Laboratories|Prostate Cencer Centre, Calgary|Northern Alberta Urology Centre|Alberta Cancer Foundation|Alberta Innovates Health Solutions|Motorcycle Ride for Dad|University Hospital Foundation - The Kaye Fund Competition","Male","40 Years to 75 Years   (Adult, Older Adult)",,"2800","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APCaRI-05","June 6, 2019","December 2021","December 2021","May 21, 2019",,"June 18, 2021","Century Clinical Research Institute, Daytona Beach, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Prostate Cancer Centre, Calgary, Alberta, Canada|Northern Alberta Urology Centre, Edmonton, Alberta, Canada|Yukon, Whitehorse, Yukon Territory, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03957252/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03957252"
40,"NCT04913545","The Senstivity and Specificity of Using Salivary miRNAs in Detection of Malignant Transformation of Oral Lesions.",,"Completed","No Results Available","Oral Premalignant Lesions","Diagnostic Test: using salivary miRNA (412,512)","the sensitivity and specificity of salivary miRNAs (412,512) to detect the malignant transformation of oral potentially malignant lesions","Cairo University","All","35 Years to 70 Years   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","19 September,2018 ,Version 2","June 5, 2019","January 7, 2020","August 7, 2020","June 4, 2021",,"June 9, 2021","Dentistry, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04913545"
41,"NCT04270006","Evaluation of Adipose Derived Stem Cells Exo.in Treatment of Periodontitis","exosomes","Recruiting","No Results Available","Periodontitis","Biological: adipose derived stem cells exosomes","change in gingival inflammation|change in pocket depth|change in attachment level|change in Bone level","Beni-Suef University","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDBSUREC/21012020/ME","February 12, 2020","September 12, 2020","October 2021","February 17, 2020",,"February 17, 2020","Beni-Suef University, Banī Suwayf, Egypt|Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04270006"
42,"NCT04338347","CAP-1002 in Severe COVID-19 Disease",,"No longer available","No Results Available","COVID-19","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells",,"Capricor Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"CAP-1002-COVID-19",,,,"April 8, 2020",,"December 1, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04338347"
43,"NCT04993378","Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy",,"Recruiting","No Results Available","Advanced Gastric Adenocarcinoma|Immunotherapy","Device: EV-array","EV-Score|Survival significance of EV-Score","Shen Lin|Peking University","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGOG-EV-1001","November 1, 2018","April 30, 2021","July 30, 2021","August 6, 2021",,"August 6, 2021","Peking University Cancer Hospital & Institute, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04993378"
44,"NCT04664738","PEP on a Skin Graft Donor Site Wound",,"Enrolling by invitation","No Results Available","Skin Graft","Biological: 10% PEP|Drug: TISSEEL|Biological: 20% PEP","Acute dose limiting toxicities (DLTs)|Maximum Tolerated Dose (MTD) of PEP|Adverse events","Steven L. Moran|Rion LLC|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-004995","March 16, 2021","July 2022","December 2022","December 11, 2020",,"January 5, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04664738"
45,"NCT04131712","Mechanisms Underlying Local and Systemic Effects of Massage",,"Recruiting","No Results Available","Muscle Atrophy","Other: Massage","Percent change in myofiber Cross Sectional Area (CSA).|Percent change in myofibrillar protein synthesis (MyoKsyn).|Percent change in serum extracellular vesicle number (EV #).|Percent change in the expression of muscle Rab27b mRNA.","Esther Dupont-Versteegden|University of Oklahoma|National Center for Complementary and Integrative Health (NCCIH)|University of Kentucky","All","18 Years to 30 Years   (Adult)","Not Applicable","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","43499|R21AT010847","August 1, 2020","June 1, 2022","June 1, 2022","October 18, 2019",,"August 2, 2021","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04131712"
46,"NCT03634098","Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics","Quid-Nash","Recruiting","No Results Available","Type2 Diabetes","Device: new quantitative imaging techniques with contast products|Diagnostic Test: blood sample|Diagnostic Test: second generation tests","To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH|To study in type 2 diabetic participants with or without liver biopsy, performance of a composite biomarker for the diagnosis of clinically significant metabolic liver diseases|To study in type 2 diabetic participants with liver biopsy, the performance of a single or composite biomarker for the diagnosis of NASH elemental lesions|To study inter-center and intra-participants reproducibility of imaging measurements. a graphical evaluation will be conducted using a representation of Bland-Altman.|To study inter-center and intra-participants reproducibility of imaging measurements.a graphical evaluation will be conducted using a representation of Bland-Altman.|To study in type 2 diabetic participants the performance of second-generation tests for the diagnosis of metabolic liver diseases|Constitution of a bio-collection","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","820","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","P171105j|2018-A00311-54","October 25, 2018","October 31, 2021","June 30, 2022","August 16, 2018",,"April 5, 2021","Hôpital Beaujon, Clichy, France",,"https://ClinicalTrials.gov/show/NCT03634098"
47,"NCT04698447","The Role of a Natural Product, Containing Nanovesicles From Citrus Limon (L.) Juice, on Different CV Risk Factors",,"Active, not recruiting","No Results Available","Metabolic Syndrome|Healthy Volunteers","Dietary Supplement: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|Dietary Supplement: Placebo (without any active ingredients)|Dietary Supplement: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS","Change from Baseline in Plasma Lipids in Healthy Subjects|Change from Baseline in Plasma Lipids in Subjects with Metabolic Syndrome|Change from Baseline in Waist Circumference in Healthy Subjects|Change from Baseline in Waist Circumference in Subjects with Metabolic Syndrome|Change from Baseline in Body Mass Index (BMI) in Healthy Subjects|Change from Baseline in Body Mass Index (BMI) in Subjects with Metabolic Syndrome|Change from Baseline in Glycemia in Healthy Subjects|Change from Baseline in Glycemia in Subjects with Metabolic Syndrome|Change from Baseline in Glycated Haemoglobin in Healthy Subjects|Change from Baseline in Glycated Haemoglobin in Subjects with Metabolic Syndrome|Change from Baseline in Subclinical Atherosclerosis in Subjects with Metabolic Syndrome|Change from Baseline in Plasma Cytokines in Subjects with Metabolic Syndrome","University of Palermo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Natural Supplement CitraVes","March 28, 2019","June 19, 2020","February 2021","January 6, 2021",,"January 6, 2021","University Hospital of Palermo, Palermo, Italy",,"https://ClinicalTrials.gov/show/NCT04698447"
48,"NCT04500769","Training Induced Muscle Exosome Release","TIMER","Recruiting","No Results Available","Metabolism","Behavioral: Acute Resistance Exercise","miR-1 abundance","John McCarthy|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","All","18 Years to 30 Years   (Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","43910|3R01DK119619-02S1","March 14, 2019","September 1, 2023","September 1, 2023","August 5, 2020",,"August 9, 2021","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04500769"
49,"NCT04578223","Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension","PAPAYA","Completed","No Results Available","Pulmonary Hypertension",,"Platelet reactivity|Concentration of extracellular vesicles from platelets, leukocytes and endothelial cells|Platelet-rich thrombus formation parameters","Medical University of Warsaw|European Health Centre Otwock","All","18 Years to 99 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","KB/138/217","July 5, 2017","November 30, 2019","September 23, 2020","October 8, 2020",,"October 9, 2020","Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Education Medical, European Health Centre Otwock, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04578223"
50,"NCT03381482","Ectosomes, New Biomarkers of Tau Pathology?","ECTAUSOME","Recruiting","No Results Available","Alzheimer Disease","Diagnostic Test: CSF drawing during spinal anaesthesia|Diagnostic Test: Fasting blood sample|Diagnostic Test: Lumbar puncture","Presence of Tau in extracellular vesicles in CSF|The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.|The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.","University Hospital, Lille","All","40 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016_59|2017-A01715-48","December 20, 2017","December 2021","December 2021","December 22, 2017",,"September 9, 2020","Hôpital Roger Salengro, CHRU, Lille, France",,"https://ClinicalTrials.gov/show/NCT03381482"
51,"NCT03674255","Echocardiography: Value and Accuracy at REst and STress","EVAREST","Enrolling by invitation","No Results Available","Coronary Artery Disease|Ischaemic Heart Disease|Angina Pectoris",,"Assessment of Prognostically Significant CAD|Examination of Medical Records|Quantification of Extracellular Vesicles (obtained from blood samples) by Flow Cytometry|Assessment of Time to Diagnosis|Analysis of Potential Cost Savings Through the Use of Novel Biomarkers By the Reduction in Unnecessary Procedures|Investigation into the use of stress echocardiography as a clinical procedure in the UK.","University of Oxford|Oxford University Hospitals NHS Trust|Royal United Hospital Bath NHS Trust|Tameside Hospital NHS Foundation Trust|Royal Berkshire NHS Foundation Trust|East Lancashire Hospitals NHS Trust|Bradford Teaching Hospitals NHS Foundation Trust|Calderdale and Huddersfield NHS Foundation Trust|Great Western Hospitals NHS Foundation Trust|Mid Essex Hospital NHS Trust|Buckinghamshire Healthcare NHS Trust|Wrightington, Wigan and Leigh NHS Foundation Trust|Chelsea and Westminster Hospital NHS Foundation Trust|Milton Keynes University Hospital NHS Foundation Trust|University Hospitals Bristol and Weston NHS Foundation Trust|North Middlesex University Hospital|Northumbria Healthcare NHS Foundation Trust|London North West Healthcare NHS Trust|St George's University Hospitals NHS Foundation Trust|Ultromics Ltd|National Institute for Health Research, United Kingdom|King's College Hospital NHS Trust|Guy's and St Thomas' NHS Foundation Trust|Poole Hospital NHS Foundation Trust|Blackpool Teaching Hospitals NHS Foundation Trust|Mid Yorkshire Hospitals NHS Trust|Northampton General Hospital NHS Trust|North West Anglia NHS Foundation Trust|Yeovil District Hospital NHS Foundation Trust|East Suffolk and North Essex NHS Foundation Trust|Nottingham University Hospitals NHS Trust|Hampshire Hospitals NHS Foundation Trust|Lantheus Medical Imaging","All","18 Years and older   (Adult, Older Adult)",,"23000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18100","March 2015","March 2020","January 2032","September 17, 2018",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT03674255"
